MARKET

KTTA

KTTA

Pasithea Therapeutics Corp
NASDAQ
0.9533
+0.0933
+10.85%
Opening 14:08 05/14 EDT
OPEN
0.9000
PREV CLOSE
0.8600
HIGH
1.045
LOW
0.8800
VOLUME
14.03M
TURNOVER
--
52 WEEK HIGH
7.50
52 WEEK LOW
0.7970
MARKET CAP
5.77M
P/E (TTM)
-0.0751
1D
5D
1M
3M
1Y
5Y
1D
Pasithea Therapeutics announces initiation of Phase 1/1b study of PAS-004
TipRanks · 6h ago
PASITHEA THERAPEUTICS ANNOUNCES INITIATION OF PHASE 1/1B STUDY OF PAS-004 IN ADULT NF1 PATIENTS AND ACTIVATION OF FIRST CLINICAL TRIAL SITE
Reuters · 7h ago
Weekly Report: what happened at KTTA last week (0505-0509)?
Weekly Report · 2d ago
3 Penny Stocks to Watch Now, 5/8/25
TipRanks · 6d ago
Pasithea Therapeutics Raises $6.3 Million in Stock Offering
TipRanks · 6d ago
Press Release: Pasithea Therapeutics Announces Closing of $5 Million Public Offering
Dow Jones · 6d ago
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 05/07 17:06
Pasithea Therapeutics 3.57M share Secondary priced at $1.40
TipRanks · 05/06 15:35
More
About KTTA
More
Pasithea Therapeutics Corp. is a biotechnology company focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases. The Company is advancing a pipeline of three therapeutic product candidates, with a focus on its lead product candidate, PAS-004, a macrocyclic mitogen-activated protein kinase, or MEK inhibitor. PAS-004 is a small molecule allosteric inhibitor of MEK 1 and 2 (MEK 1/2) for potential use in the treatment of a range of RASopathies, including neurofibromatosis type 1 (NF1) and a number of oncology indications, among others. Its remaining two programs, PAS-001 and PAS-003, are in the earlier stages of development and are based on novel targets for the treatment of CNS disorders that it believes address limitations in the treatment paradigm of the indications it plans to address, which are amyotrophic lateral sclerosis (ALS) for its PAS-003 program, and schizophrenia for its PAS-001 program.
Recently
Symbol
Price
%Change

Webull offers Pasithea Therapeutics Corp stock information, including NASDAQ: KTTA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KTTA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KTTA stock methods without spending real money on the virtual paper trading platform.